The aberrant expression of mucin-type O-glycosylation plays important roles in cancer malignancy. The polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts) are a family of conserved enzymes that initiate the mucin-type O-glycosylation in cells. In human, consistent up-or downregulation of ppGalNAc-Ts expression during cancer development has been frequently reported. Here, we provide evidence that ppGalNAc-T4 shows a stage-dependent expression at the different stages of colorectal cancer (CRC) in the 62 pair-matched tumor/normal tissues. In detail, ppGalNAc-T4 expression is significantly induced at stage I and II but not at stage III and IV. Overexpression of ppGalNAc-T4 in CRC cells enhances colony formation and sphere formation suggesting an important role of ppGalNAc-T4 in tumorigenesis. Conversely, knockdown of ppGalNAc-T4 in CRC cells increases the cell migration and invasion, and leads to an epithelial-mesenchymal transition-like transition. Further analysis suggests that loss of ppGalNAc-T4 contributes to the dedifferentiation of CRC and high expression of ppGalNAc-T4 correlates to a good prognosis of patients. Taken together, our results not only demonstrate a stagedependent expression of ppGalNAc-T4 in CRC progression, but also suggest that such stage-dependent expression may contribute to the tumorigenesis at the early stage and promote cell migration and invasion at the advanced stage.
The aberrant expression of mucin-type O-glycosylation plays important roles in cancer malignancy. The polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts) are a family of conserved enzymes that initiate the mucin-type O-glycosylation in cells. In human, consistent up-or downregulation of ppGalNAc-Ts expression during cancer development has been frequently reported. Here, we provide evidence that ppGalNAc-T4 shows a stage-dependent expression at the different stages of colorectal cancer (CRC) in the 62 pair-matched tumor/normal tissues. In detail, ppGalNAc-T4 expression is significantly induced at stage I and II but not at stage III and IV. Overexpression of ppGalNAc-T4 in CRC cells enhances colony formation and sphere formation suggesting an important role of ppGalNAc-T4 in tumorigenesis. Conversely, knockdown of ppGalNAc-T4 in CRC cells increases the cell migration and invasion, and leads to an epithelial-mesenchymal transition-like transition. Further analysis suggests that loss of ppGalNAc-T4 contributes to the dedifferentiation of CRC and high expression of ppGalNAc-T4 correlates to a good prognosis of patients. Taken together, our results not only demonstrate a stagedependent expression of ppGalNAc-T4 in CRC progression, but also suggest that such stage-dependent expression may contribute to the tumorigenesis at the early stage and promote cell migration and invasion at the advanced stage.
Introduction
Colorectal cancer (CRC) is the second most prevalent cancer in females and third in males worldwide, and the number of CRC patients has been growing in recent years [1, 2] . Despite the development of colonoscopy for diagnosis and improved surgical treatment for radical dissection, there are still 693 900 deaths each year caused by CRC [2] . The main cause of death is the recurrence and distant metastasis of CRC. More than 50% of all CRC patients suffered from recurrence or developed distant metastasis even when the primary tumor was successfully resected [3] [4] [5] [6] . Therefore, it is urgent to improve the therapeutic treatment of CRC or develop efficient biomarkers for early detection and prognostic prediction.
Altered glycosylation is a common event in tumorigenic transformation. However, the glycan changes in malignant cells are not random [7] [8] [9] [10] . There is only a very limited subset of oligosaccharides enriched as a consequence of dysregulated glycosyltransferases and glycosidases during tumorigenesis and malignant progression [8, 11] . Cancer-associated glycoconjugates in serum and tissue have been used as important biomarkers for disease progression [12] [13] [14] [15] . Mucin-type O-glycosylation is an evolutionarily conserved protein modification present on membrane-bound and secreted proteins [16, 17] , of which aberrant expression has long been associated with tumor malignancy [18, 19] . In mammals, mucin-type O-glycosylation is initiated by a family of 20 polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts), which catalyze the formation of an a-anomeric linkage, namely transferring GalNAc to the hydroxyl group of serine or threonine residues [20] [21] [22] [23] . Accumulating reports indicate that ppGalNAc-Ts are involved in the regulation of tumorigenesis and malignancy. As examples, ppGalNAc-T13, which is highly expressed in brain and lungs, is associated with lung cancer progression [20, 24] ; in colon cancer, the aberrant expression of ppGalNAc-T12 was reported several years ago [25, 26] ; recently, the upregulated expression of ppGalNAc-T6 has also been found to be important for colon cancer; and loss of ppGalNAc-T6 in CRC cells leads to a pattern of reduced proliferation, normalized cell-cell adhesion and formation of crypts in tissue cultures [27] . These results suggest that different ppGalNAc-Ts may play distinctive roles in different types of cancer. This may not be surprising as it has been clearly demonstrated that different ppGalNAc-Ts have unique expression pattern in specific tissues and have partially overlapping but different substrate specificities [28, 29] . Therefore, elucidation of the mechanistic roles of ppGalNAc-Ts in cancer may contribute to a better understanding of the mechanisms underlying cancer progression and prove relevant for clinical translation in therapeutic treatment, early detection and prognostic prediction.
Recently, several reports indicate the dynamic expression of glycosyltransferases during cancer progression [30] [31] [32] [33] , but little is known of its importance. In the current study, we report that ppGalNAc-T4 shows a stage-dependent expression at the different stages of CRC. ppGalNAc-T4 is induced at stage I and II but not at stage III or IV as compared with paired normal tissues. Overexpression of ppGalNAc-T4 in CRC cells promotes colony formation and sphere formation, while knockdown of ppGalNAc-T4 leads to an enhancement of cell migration and invasion. Further study shows that loss of ppGalNAc-T4 may contribute to the dedifferentiation of CRC. Taken together, our results not only demonstrate the stage-dependent expression of ppGalNAc-T4 in CRC, but also indicate the importance of such stagedependent expression of O-glycosyltransferase in CRC progression.
Results

Stage-dependent expression of ppGalNAc-T4 in CRC progression
Aberrant expression of ppGalNAc-T4 has been reported in hepatocellular carcinoma and renal cancer [34, 35] . However, the function of ppGalNAc-T4 in CRC remains unknown. To investigate the roles of ppGalNAc-T4 in CRC, we examined the expression of ppGalNAc-T4 in 62 CRC specimens from stage I to stage IV as well as their paired normal tissues using a commercial antibody against ppGalNAc-T4. The high specificity of this antibody was confirmed by western blot using purified ppGalNAc-T enzyme and different FLAG-tagged ppGalNAc-Ts overexpressed by HEK293T cells (Fig. 1E and Fig. S1 ). The enzyme was purified from a HEK293T cell culture as described previously [36] . The clinical and pathological factors are indicated in Table 1 . Western blot analysis showed that the expression of ppGalNAc-T4 was significantly increased at stages I and II as compared with their matched normal tissues. But when CRC developed to stage III or IV, no statistical difference was observed between the tumors and their paired normal tissues (Fig. 1A,B and Fig. S2 ). In addition, the expression of ppGalNAc-T4 in CRC at stages I and II was significantly higher than that at stages III and IV (Fig. 1C) . These observations were further confirmed by immunohistochemical (IHC) staining of CRC tissues (E) Specificity of antippGalNAc-T4 antibody (rabbit polyclonal antibody; Proteintech, 12897-1-AP) with regard to the different purified ppGalNAc-Ts. n.s., not significant; *P < 0.05, **P < 0.01 by paired t test or Mann-Whitney U test. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the loading control.
at different stages (Fig. 1D ). Taken together, the results above demonstrate that ppGalNAc-T4 shows a stage-dependent expression in CRC progression.
ppGalNAc-T4 expression contributes to colony formation, sphere formation but not proliferation of CRC cells
Next, to investigate the biological meaning underlying this stage-dependent expression, we first checked the expression of ppGalNAc-T4 in different CRC cell lines including HCT116, HT29, SW480, SW620 and RKO, which are commonly used for the investigation of mechanisms underlying CRC tumorigenesis and progression. Western blot and quantitative real-time PCR (qPCR) analyses showed that ppGalNAc-T4 was highly expressed in HT29 and SW480 cell lines, but not in HCT116, SW620 and RKO cell lines ( Fig. 2A,B) . Therefore, we knocked down ppGalNAc-T4 expression by ppGalNAc-T4-targeting short hairpin RNA (shRNA) in SW480 and HT29 cell lines. The knockdown efficiency was confirmed not only at the protein level (Fig. 2C,G) , but also at the O-glycosylation level using Helix pomalia (HPA; binds Tn carbohydrate antigen) and Arachis hypogaea (PNA; binds T carbohydrate antigen) lectins ( Fig. 2D,H) . Knockdown of ppGalNAc-T4 had little effect on the expression of other ppGalNAc-Ts (data not shown). Subsequent cell counting kit-8 (CCK-8) experiments showed no significant difference in cell proliferation between knockdown cells and their control cells (Fig. 2E,I ). However, intriguingly, colony formation was significantly inhibited after the silencing of ppGalNAc-T4 in both cell lines (Fig. 2F ,J). These results suggest that ppGalNAc-T4 may be involved in CRC tumorigenesis. To confirm this hypothesis, we overexpressed ppGalNAc-T4 in SW620 and HCT116 cells. The high expression of ppGalNAc-T4 was validated by western blot (Fig. 3A ,E) and the increased O-glycosylation by lectin blot using HPA and PNA lectins (Fig. 3B,F) . Overexpression of ppGalNAc-T4 had little effect on the expression of other ppGalNAc-Ts (data not shown). Consistent with the observations after ppGalNAc-T4 knockdown, no significant difference was observed in cell proliferation after ppGalNAc-T4 overexpression ( Fig. 3C ,G), while forced expression of ppGalNAc-T4 led to an increased ability to form colonies in both cell lines ( Fig. 3D ,H). To further confirm the effects of ppGalNAc-T4 in tumorigenesis, we also examined the ability to form spheres in ppGalNAc-T4-overexpressing SW620 cells. Although there was no difference in the number of spheres of diameter 0-50 lm, ppGalNAc-T4 overexpression resulted in a significant enhancement in the spheres of diameter 50-150 lm (Fig. 3I ). These results indicate that ppGalNAc-T4 expression contributes to CRC cell colony and cell sphere formation, suggesting that the change of ppGalNAc-T4 expression may be important for CRC tumorigenesis.
Loss of ppGalNAc-T4 may promote the dedifferentiation of CRC
As shown above, ppGalNAc-T4 expression in CRC at stages I and II was significantly higher than that at stages III and IV. Considering that stages I and II mainly consist of the well-or moderately differentiated CRC but CRC at stages III and IV is largely poorly differentiated (Table 1) , we checked whether ppGalNAc-T4 expression was statistically associated with CRC differentiation. We performed the IHC analysis of ppGalNAc-T4 in well/ moderately differentiated (n = 7) and poorly differentiated (n = 5) CRC and their paired normal tissues. In each sample, five fields were selected randomly for further analysis. The expression of ppGalNAc-T4 was scored and categorized as 0, +1, +2 or +3 according to the intensity of staining (Fig. S3A) . According to the scoring results based on IHC staining, we found that ppGalNAc-T4 was mainly expressed at a relatively high level in well/moderately differentiated tissues but not in poorly differentiated tissues (Fig. 4A,B and Fig. S3B ). We also checked the ppGalNAc-T4 expression by western blot using the CRC specimens and their paired normal tissues. Consistent with IHC analysis, the ratio of the density (tumor/normal) obtained by immunoblot images in Fig. 1 showed that high expression of ppGalNAc-T4 was associated with well/moderately differentiated CRC (Fig. 4C) . To further confirm these observations, we examined the expression of ppGalNAc-T4 in different CRC cell lines in the ONCOMINE database (www.oncomine.org). In agreement with our IHC and western blot analyses, ppGalNAc-T4 was highly expressed in CRC cell lines that have been defined as colon-like cells previously [37] , but not in those defined as undifferentiated cells including SW620, SW48 and HCT-15 cell lines (Fig. 4D) . We wondered whether ppGalNAc-T4 expression could affect CRC differentiation. As CRC is usually derived from epithelial tissue of the colon and rectum mucus layer, we checked the expression of several epithelial and mesenchymal markers after ppGalNAc-T4 overexpression or knockdown. As shown in Fig. 4E , knockdown of ppGalNAc-T4 in SW480 and HT29 cells reduced the expression of the epithelial markers E-cadherin and EpCAM, while enhanced the expression of mesenchymal markers Ncadherin and b-catenin. Conversely, overexpression of ppGalNAc-T4 in SW620 cells led to an increase in the expression of E-cadherin and epithelial cell adhesion molecule (EpCAM), but a decrease in the expression of N-cadherin and b-catenin. Taken together, these results suggest that loss of ppGalNAc-T4 may contribute to the dedifferentiation of CRC.
Low expression of ppGalNAc-T4 promotes cell migration and invasion, and is associated with poor prognosis of CRC patients Given these molecular changes of epithelial-mesenchymal transition (EMT) markers above, we checked whether ppGalNAc-T4 expression could affect the cell migration by a wound healing assay, as a phenotypic hallmark of EMT is the stimulation of cell migration. Silencing of ppGalNAc-T4 in SW480 cells significantly increased cell migration (Fig. 5A) . Conversely, overexpression of ppGalNAc-T4 inhibited the cell migratory ability (Fig. 5B ). These observations were further confirmed by a transwell assay. In addition to cell migration, silencing of ppGalNAc-T4 also promoted the cell invasion as the invasive ability of ppGalNAc-T4 knockdown cell was significantly increased as compared with the control cells (Fig. 5C) . On the contrary, overexpression of ppGalNAc-T4 lowered the invasive ability of SW620 cells (Fig. 5D) . These results suggest that poor expression of ppGalNAc-T4 at the advanced stage of CRC may contribute to the cell migration and invasion of tumor cells. Considering that migratory and invasive ability is usually associated with tumor malignancy, we wondered whether ppGalNAc-T4 was associated with the prognosis of CRC patients. To test this, we compared the prognosis of CRC patients with the high or low expression of ppGalNAc-T4. Kaplan-Meier analysis revealed that the low expression group of CRC patients had both shorter overall survival and relapse-free survival time. The cutoff value of ppGalNAc-T4 expression (Ratio tumor/normal = 1.2) was obtained by Youden's index from a receiver operating characteristic (ROC) curve (Fig. 5E,F) . Taken together, these results indicate that low expression of ppGalNAc-T4 in CRC may promote cell migration and invasion, and is associated with poor prognosis of patients.
Discussion
The aberrant expression of glycosylation is a common feature of cancer cells. Instead of consistent up-or down-regulation, recently several studies have indicated stage-dependent change of glycosyltransferases 2) was based on Youden's index from the ROC curve. The data were obtained from three independent experiments and presented as mean AE SD; *P < 0.05, **P < 0.01 by paired t test or Mann-Whitney U test.
during tumor progression [31] [32] [33] . In spite of these interesting observations, little is known on the importance of such a manner of expression in cancer progression. In the current study, we show that ppGalNAc-T4 is induced in CRC at stages I and II (non-metastatic stages) but not at stages III and IV (metastatic stages) as compared with their paired normal tissues. Overexpression of ppGalNc-T4 in CRC cells enhances colony formation and sphere formation abilities, which are important features for cell tumorigenicity. Conversely, silencing of ppGalNc-T4 increases cell migration and invasion. Furthermore, depletion of ppGalNAc-T4 contributes to the dedifferentiation of CRC and correlates to the poor prognosis of CRC patients. Taken together, our results not only demonstrate the stage-dependent expression of ppGalNc-T4 in CRC, but also indicate the influences of such an alteration on tumor cell behavior, which provides a plausible explanation for the stage-dependent expression of ppGalNAc-T4 in CRC.
Accumulating evidence indicates that the aberrant expression of ppGalNAc-Ts in cancer is not random but has important pathological meanings [30, 38, 39] . Here, we show that high expression of ppGalNAc-T4 contributes to colony formation and sphere formation but not to cell proliferation. Considering that the colony formation and sphere formation abilities could partially indicate the tumorigenic potentials of tumor cells, we think that upregulation of ppGalNAc-T4 at the early stage of CRC may contribute to its tumorigenesis. Like ppGalNAc-T4, ppGalNAc-T1 and ppGalNAc-T14 have also been implicated in the regulation of cell tumorigenesis in different types of carcinomas including bladder cancer and breast cancer [40] [41] [42] . These observations suggest that different ppGalNAcTs may have similar functions but are associated with different tumors. One reasonable explanation for this could be that different ppGalNAc-Ts have partially overlapping but different substrate specificities. Therefore, to elucidate the different mechanisms of different ppGalNAc-Ts in cancer, there is a need for further investigation into the substrate specificity of each ppGalNAc-T.
Unlike the upregulation of ppGalNAc-T4 at the early stage, this enzyme is poorly expressed at the advanced stages of CRC (stages III and IV) and correlates to a poor prognosis of CRC patients. Knockdown of ppGalNAc-T4 results in an increased cell migration and invasion of CRC cells as well as the dedifferentiation of CRC. Given migratory and invasive abilities are essential for tumor metastasis and poor differentiation is usually associated with tumor malignancy such as anti-apoptosis [43, 44] , it is reasonable to think that the poor expression of ppGalNAc-T4 at stages III and IV may confer tumor cells with metastatic potentials and anti-apoptotic abilities, leading to the poor prognosis of CRC patients. Similar to ppGalNAc-T4, ppGalNAc-T1, T2, T3, T6, T7 and T13 have been reportedly involved in cell migration or invasion in various types of cancer [45] [46] [47] [48] [49] . Among these, ppGalNAc-T3 and ppGalNAc-T6 are also majorly expressed in welldifferentiated CRC tissues [27, 50] , indicating that ppGalNAc-T3, ppGalNAc-T4 and ppGalNAc-T6 may have more similar functions in CRC. In spite of such similarity, unlike ppGalNAc-T4, loss of ppGalNAc-T6 has little effect on EMT, suggesting that each ppGalNAc-T may have distinct mechanisms in the regulation of cancer cell behaviors.
Like ppGalNA-T4, it has been reported that sialyltransferase ST6GAL1 [31] is also enriched at the early stage but not at the advanced stage. Considering cancer progression involves a series of complex processes and each process corresponds to a specific cell status, we think that the stage-dependent change during the cancer progression may be common among the proteins that are highly involved in regulation of the cell behaviors. Such a manner of expression, as we demonstrate in the case of ppGalNA-T4 here, may play important roles in regulating tumor progression.
The human GALNT gene family encoding 20 homologous genes can be further divided into subfamilies of highly related isoforms. Several studies have shown that many of the subfamily members are both closely genetically and closely functionally related [16, 21] . However, despite the potential redundancy of GalNActransferases within a given cell, the functional importance of individual members relates to their temporal and spatial expression in normal and disease situations.
Increasing evidence indicates that ppGalNAc-Ts play important roles in the regulation of physiological and pathological processes by affecting the different substrate proteins [27, 30, 51, 52] . Here, we show that ppGalNA-T4 is involved in the regulation of cell differentiation of CRC by affecting the expression of E-cadherin, Ncadherin, EpCAM and b-catenin. Since E-cadherin and EpCAM are both mucin-type O-glycosylated proteins [53, 54] , it is possible that ppGalNA-T4 regulates the CRC differentiation partially by affecting the O-glycosylation levels of these proteins. Clearly, there may exist other substrate proteins and further investigation is needed to identify them. However, our study here demonstrates a stage-dependent expression of ppGalNAc-T4 in CRC progression and its importance in regulating tumor cell behavior, which may contribute to our better understanding of the mechanisms underlying CRC progression and the prediction of the prognosis of CRC patients.
Materials and methods
Tissue specimens
A total of 73 CRC patients were recruited from Ruijin Hospital (Shanghai, China), from May 2009 to Jun 2012. The 62 specimens for western blot included pathological stages ranging from I to IV (stage I, n = 21; stage II, n = 13; stage III, n = 21; and stage IV, n = 7), with different pathological grade (well differentiated, n = 4; moderately differentiated, n = 40; and poorly differentiated, n = 18). The 12 specimens for IHC staining included well-differentiated tumor, n = 2; moderately differentiated tumor, n = 5; and poorly differentiated tumor, n = 5. The CRC was staged according to criteria of the Union for International Cancer Control (UICC), and the pathological information was collected from the histopathological reports of CRC diagnosed at the department of pathology of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The tumor tissue and paired normal colonic tissues that located approximately 10 cm to the distal edge of the tumor were stored in liquid nitrogen for further analysis. The protein extraction, the standard for follow-up, and the inclusion and exclusion criteria of patients were performed as described in [33] . The patients were followed up either for 90 months or until death. The time of death and local or distant recurrence were recorded. The study methodologies were approved by the ethics committee of Ruijin Hospital and conformed to the standards set by the Declaration of Helsinki. The experiments were undertaken with the understanding and written consent of each subject.
Cell lines and cell culture
The HEK293T and SW620, SW480, HCT116, HT29 and RKO cell lines were purchased from ATCC (Manassas, VA, USA). The HEK293T cells were cultured in high glucose Dulbecco's modified Eagle's medium (DMEM) with 10% FBS; HCT116 and HT29 cells were cultured in McCoy's 5a medium with 10% FBS under a humidified atmosphere at 37°C in an incubator; and SW480 and SW620 cells were maintained in Leibovitz's L15 medium (HyClone, Logan, UT, USA) with 10% FBS under a humidified atmosphere at 37°C without CO 2 addition.
Establishment of ppGalNAc-T4-overexpressing or -knockdown CRC cells
The full length of ppGalNAc-T4 was inserted in the PCDH1 vector and the plasmids were transfected into HEK293T cells using a Lipofectamine 2000 transfection reagent; 48-72 h later, the culture medium was collected, filtered and then used to infect HCT116 and SW620 cells. ppGalNAc-T4-overexpressing cells were obtained by antibiotic selection (puromycin 3 lgÁmL À1 ). 
Quantitative real-time PCR analysis
Total RNA was extracted from cells by Isol-RNA lysate reagent (Takara, Shiga, Japan). cDNA was obtained from the reverse-transcription of 1 lg total RNA after treated with a PrimeScript RT reagent Kit to erase gDNA (Takara). The sequences of primers for qPCR were: ppGalNAc-T4 ( 
Immunohistochemical staining
The tumor and paired normal tissue sections (4 lm) were deparaffinized and dehydrated, and then treated by 3% H 2 O 2 at room temperature for 10 min to block endogenous peroxidase activity. Next, the tissue sections were incubated with citrate buffer for the retrieval of the antigen. Then the tissues were blocked with 10% goat serum at room temperature for 30 min, followed by incubating with anti-ppGalNAc-T4 antibody (1 : 100) at 4°C overnight. Finally the tissue slides were counterstained with hematoxylin and eosin (H&E). The expression of ppGalNAc-T4 was scored and categorized as 0, +1, +2 or +3 according to the intensity of staining according to the reference and was analyzed by Fisher's exact test [55, 56] .
Migration and invasion assay
The cell migration and invasion assays were performed using 8-lm transwell chambers (Corning, New York, USA) with 24-well plates. The migration assays were conducted using transwell chambers precoated with 1% collagen I, while the invasion assays used Matrigel (BD Biosciences, San Jose, CA, USA)-coated chambers; 1 9 10 5 SW620 cells and 1.5 9 10 5 SW480 cells were suspended in 500 lL serum-free medium and seeded into the upper chamber; and medium with 10% FBS was added into the lower chamber. After incubation for 24 h for the migration assay and 48 h for the invasion assay, cells were fixed with 4% paraformaldehyde at room temperature for 30 min, and then stained with 0.1% crystal violet at 37°C for 1 h. The stained cells were counted in five fields with random choice.
Wound healing assay
The SW480 and SW620 cells were seeded into 12-well plates until the cells reached more than 95% confluence, and then wounded with pipette tips. The floating cells were removed using fresh medium and cultured at 37°C without CO 2 addition. The wound closing was photographed every 8 h.
CCK-8 assay
Cells (SW620 mock, SW620 ppGalNAc-T4 OE, SW480 NC, SW480 ppGalNAc-T4 sh1 and SW480 ppGalNAc-T4 sh2) were incubated in 96-well plates. Each group of cells were parallel repeated for five times. The proliferation of the cells was tested at times 0, 24, 48, 72 and 96 h after treatment with CCK-8 (Dojindo Molecular Technologies, Inc, Shanghai, China) at 37°C for 1.5 h and the absorbance was determined with a spectrophotometer.
Colony formation assay
One thousand cells were seeded in six-well plates, and fresh medium was added every 3 days. The cells were cultured for about 15 days, until visible colonies were observed. Then the medium was discarded, and the colonies were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The efficiency of colony formation was estimated by the number of the colonies.
Sphere formation assay
Mammosphere culture was performed in a serum-free DMEM/F12 medium with B27 (Thermo Fisher Scientific, Waltham, MA, USA), 20 ngÁmL À1 epidermal growth factor and 10 ngÁmL À1 basic fibroblast growth factor. Cells were suspended and seeded in the six-well ultralow attachment plate at a density of 10 cellsÁlL À1 with mammosphere culture. Single cell status was confirmed by microscopy. Fresh mammosphere culture was added every 3 days. Seven days later, the mammospheres formed were observed and counted by microscopy.
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